Jenny C. Chang, MD

Emily Herrmann Chair in Cancer Research & Director, Cancer Center
Professor of Cancer, Institute for Academic Medicine
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Biography

Dr. Jenny C. Chang is the Director of Houston Methodist Cancer Center and Emily Herrmann Chair in Cancer Research in Houston, Texas. She obtained her medical degree at Cambridge University in England, and then completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research in the United Kingdom. She was also awarded a research doctorate from the University of London. Her recent work has focused on the intrinsic therapy resistance of cancer stem cells, which has led to several publications and international presentations. Dr. Chang’s clinical research aims to evaluate novel biologic agents in breast cancer patients.

Description of Research

Dr. Chang has worked in the field of tumor-initiating cells for more than ten years. After her discovery that tumor-initiating cells are chemo-resistant, and that targeting the EGFR/HER2 pathway can decrease this subpopulation, Dr. Chang has played a key role in demonstrating some of the limitations and mechanisms of tumor-initiating cells (Creighton et al., 2009; Li et al., 2008). Her work is now focused on the mechanisms that regulate TICs, as well as initiating and planning clinical trials that target this critical tumor initiating subpopulation. She is also interested in characterizing the cross-talk between these different pathways that may lead to mechanisms of resistance, and has identified some of the chief regulatory pathways involved in TIC self-renewal. She is a world-renown clinical investigator, credited as one of the first to describe intrinsic chemo-resistance of tumor-initiating cells.

Areas Of Expertise

Breast cancer Cancer Stem cells High throughput
Education & Training

MD, University of Cambridge
Research Doctorate, University of London
Publications

Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database
Lewis, GD, Xing, Y, Haque, WM, Patel, T, Schwartz, M, Chen, A, Farach, AM, Hatch, SS, Butler, EB, Chang, JC & Teh, BS 2019, Cancer Communications, vol. 39, no. 1, 60. https://doi.org/10.1186/s40880-019-0406-4

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Patel, T, Ensor, Jr. JE, Creamer, SL, Boone, T, Rodriguez, AA, Niravath, PA, Darcourt, J, Meisel, JL, Li, X, Zhao, J, Kuhn, JG, Rosato, RR, Qian, W, Belcheva, A, Schwartz, MR, Kaklamani, VG & Chang, JC 2019, Breast Cancer Research, vol. 21, no. 1, 100. https://doi.org/10.1186/s13058-019-1186-0

Developing a model to predict accrual to cancer clinical trials: Data from an NCI designated cancer center
Iruku, P, Goros, M, Gelfond, J, Chang, JC, Padalecki, S, Mesa, R & Kaklamani, VG 2019, Contemporary Clinical Trials Communications, vol. 15, 100421. https://doi.org/10.1016/j.conctc.2019.100421

Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression
La Belle Flynn, A, Calhoun, BC, Sharma, A, Chang, JC, Almasan, A & Schiemann, WP 2019, Nature Communications, vol. 10, no. 1, 3668. https://doi.org/10.1038/s41467-019-11640-9

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
Veeraraghavan, J, De Angelis, C, Mao, R, Wang, T, Herrera, S, Pavlick, AC, Contreras, A, Nuciforo, P, Mayer, IA, Forero, A, Nanda, R, Goetz, MP, Chang, JC, Wolff, AC, Krop, IE, Fuqua, SAW, Prat, A, Hilsenbeck, SG, Weigelt, B, Reis-Filho, JS, Gutierrez, C, Osborne, CK, Rimawi, MF & Schiff, R 2019, Annals of Oncology, vol. 30, no. 6, mdz076, pp. 927-933. https://doi.org/10.1093/annonc/mdz076

Erratum: Triple-negative breast cancers with amplication of JAK2 at the 9p24 locus demonstrate JAK2-specic dependence (Science Translational Medicine (2019) 11, 476, (eaaw6162), 10.1126/scitranslmed.aaw6162)
Balko, JM, Schwarz, LJ, Luo, N, Estrada, MV, Giltnane, JM, Dávila-González, D, Wang, K, Sánchez, V, Dean, PT, Combs, SE, Hicks, D, Pinto, JA, Landis, MD, Doimi, FD, Yelensky, R, Miller, VA, Stephens, PJ, Rimm, DL, Gómez, H, Chang, JC, Sanders, ME, Cook, RS & Arteaga, CL 2019, Science Translational Medicine, vol. 11, no. 476, eaaw6162. https://doi.org/10.1126/scitranslmed.aaw6162

Cancer therapeutic targeting using mutant–p53-specific siRNAs
Ubby, I, Krueger, C, Rosato, RR, Qian, W, Chang, JC & Sabapathy, K 2019, Oncogene. https://doi.org/10.1038/s41388-018-0652-y

The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast
Lewis, GD, Xing, Y, Haque, WM, Patel, T, Schwartz, MR, Chen, AC, Farach, AM, Hatch, SS, Butler, EB, Chang, JC & Teh, BS 2019, Breast Journal. https://doi.org/10.1111/tbj.13432

Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases
Liu, ZB, Ezzedine, NE, Eterovic, AK, Ensor, Jr. JE, Huang, HJ, Albanell, J, Choi, DS, Lluch, A, Liu, Y, Rojo, F, Wong, H, Martínez-Dueñas, E, Guerrero-Zotano, Á, Shao, ZM, Darcourt, J, Mills, GB, Dave, B & Chang, JC 2019, Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-019-05374-x

Activating Transcription Factor 4 Modulates TGFß-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
González-González, A, Muñoz-Muela, E, Marchal, JA, Cara, FE, Molina, MP, Cruz-Lozano, M, Jiménez, G, Verma, A, Ramírez, A, Qian, W, Chen, W, Kozielski, AJ, Elemento, O, Martín-Salvago, MD, Luque, RJ, Rosa-Garrido, C, Landeira, D, Quintana-Romero, M, Rosato, RR, García, MA, Ramirez-Tortosa, CL, Kim, H, Rodriguez-Aguayo, C, Lopez-Berestein, G, Sood, AK, Lorente, JA, Sánchez-Rovira, P, Chang, JC & Granados-Principal, S 2018, Clinical Cancer Research, vol. 24, no. 22, pp. 5697-5709. https://doi.org/10.1158/1078-0432.CCR-17-3125

A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes
Stubbins, R, He, T, Yu, X, Puppala, M, Ezeana, CF, Chen, S, Valdivia y Alvarado, M, Ensor, J, Rodriguez, A, Niravath, P, Chang, J, Wong, STC & Patel, T 2018, JCO Clinical Cancer Informatics, no. 2, pp. 1-11. https://doi.org/10.1200/CCI.18.00054

Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models
Rosato, RR, Dávila-González, D, Choi, DS, Qian, W, Chen, W, Kozielski, AJ, Wong, H, Dave, B & Chang, JC 2018, Breast Cancer Research, vol. 20, no. 1, 108. https://doi.org/10.1186/s13058-018-1037-4

Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple-negative breast cancer
Davila-Gonz alez, D, Choi, DS, Rosato, RR, Granados-Principal, SM, Kuhn, JG, Li, WF, Qian, W, Chen, W, Kozielski, AJ, Wong, H, Dave, B & Chang, JC 2018, Clinical Cancer Research, vol. 24, no. 5, pp. 1152-1162. https://doi.org/10.1158/1078-0432.CCR-17-1437

The ERß4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERß variants ERß2 and ERß5 increase aggressiveness of TNBC by regulation of hypoxic signaling
Faria, M, Karami, S, Granados-Principal, S, Dey, P, Verma, A, Choi, DS, Elemento, O, Bawa-Khalfe, T, Chang, JC, Strom, AM & Gustafsson, J-A 2018, Oncotarget, vol. 9, no. 15, pp. 12201-12211. https://doi.org/10.18632/oncotarget.24134

NO and COX2: Dual targeting for aggressive cancers
Davila-Gonzalez, D, Chang, JC & Billiar, TR 2017, Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 52, pp. 13591-13593. https://doi.org/10.1073/pnas.1717440114

HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway
Liu, Y, Choi, DS, Sheng, J, Ensor, JE, Liang, DH, Rodriguez-Aguayo, C, Polley, A, Benz, S, Elemento, O, Verma, A, Cong, Y, Wong, H, Qian, W, Li, Z, Granados-Principal, S, Lopez-Berestein, G, Landis, MD, Rosato, RR, Dave, B, Wong, S, Marchetti, D, Sood, AK & Chang, JC 2017, Stem Cell Reports. https://doi.org/10.1016/j.stemcr.2017.11.010

Molecular characterization of breast cancer CTCs associated with brain metastasis
Boral, D, Vishnoi, M, Liu, HN, Yin, W, Sprouse, ML, Scamardo, A, Hong, DS, Tan, TZ, Thiery, JP, Chang, JC & Marchetti, D 2017, Nature communications, vol. 8, no. 1, 196. https://doi.org/10.1038/s41467-017-00196-1

The lncRNA BORG Drives Breast Cancer Metastasis and Disease Recurrence
Gooding, AJ, Zhang, B, Jahanbani, FK, Gilmore, HL, Chang, JC, Valadkhan, S & Schiemann, WP 2017, Scientific Reports, vol. 7, no. 1, 12698. https://doi.org/10.1038/s41598-017-12716-6

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Rimawi, MF, de Angelis, C, Contreras, A, Pareja, F, Geyer, FC, Burke, KA, Herrera, S, Wang, T, Mayer, IA, Forero, A, Nanda, R, Goetz, MP, Chang, JC, Krop, IE, Wolff, AC, Pavlick, AC, Fuqua, SAW, Gutierrez, C, Hilsenbeck, SG, Li, MM, Weigelt, B, Reis-Filho, JS, Kent Osborne, C & Schiff, R 2017, Breast Cancer Research and Treatment, pp. 1-10. https://doi.org/10.1007/s10549-017-4533-9

A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): Responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67
Jovanovic, B, Mayer, IA, Mayer, EL, Abramson, VG, Bardia, A, Sanders, ME, Kuba, MG, Estrada, MV, Beeler, JS, Shaver, TM, Johnson, KC, Sanchez, V, Rosenbluth, JM, Dillon, PM, Forero-Torres, A, Chang, JC, Meszoely, IM, Grau, AM, Lehmann, BD, Shyr, Y, Sheng, Q, Chen, SC, Arteaga, CL & Pietenpol, JA 2017, Clinical Cancer Research, vol. 23, no. 15, pp. 4035-4045. https://doi.org/10.1158/1078-0432.CCR-16-3055

Live Chat Available